tbuckley/cabot-search huggingface dataset:
Effects of freezing/thawing on the mechanical properties of decellularized lungs
Authors: Paula Naomi Nonaka, Noelia Campillo, Juan José Uriarte, Elena Garreta, Esther Melo, Luis Vicente Franco de Oliveira, Daniel Navajas, Ramon Farré
Journal: European Respiratory Journal (2013)

Lung bioengineering based on decellularized organ scaffolds is a potential alternative for transplantation. Freezing/thawing, which is a usual procedure in organ decellularization and storage, could modify the mechanical properties of the lung scaffold and reduce the performance of the bioengineered lung when subjected to the physiological breathing cycles. The aim of this study was to determine the effects of repeated freezing/thawing on the mechanical properties of decellularized lungs in the physiological pressure-volume regime associated with normal ventilation. To this end, the lungs of 15 mice (C57BL/6, female, 17-22 g) were excised and decellularized using a conventional protocol not involving organ freezing and based on sodium dodecyl sulfate detergent. Subsequently, the mechanical properties of the acellular lungs were measured before and after subjecting them to 3 consecutive cycles of freezing/thawing: room temperature, -20°C, -80°C, -20°C and room temperature for each cycle. The resistance (RL) and elastance (EL) of the decellularized lungs were computed by linear regression fitting of the recorded signals (tracheal pressure, flow and volume) during mechanical ventilation (tidal volume = 10 ml/kg, frequency = 60 breath/min, positive end-expiratory pressure = 2 cmH2O). RL was not significantly modified by freezing-thawing: from 0.88±0.37 to 0.90±0.38 cmH2O• s• mL-1 (mean±SE). EL slightly increased from 64.4±11.1 to 73.0±16.3 cmH2O• mL-1 after the three freeze-thaw cycles (p=0.0013). In conclusion, the process of organ freezing/thawing that is commonly used for both organ decellularization and storage induces only minor changes in the ventilation mechanical properties of the organ scaffold.
Low Rbm3 Protein Expression Correlates with Clinical Stage, Prognostic Index and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer
Authors: S. Olofsson, B. Nodin, A. Gaber, J. Eberhard, M. Uhlén, E. Cavallin-Ståhl, K. Jirström
Journal: Annals of Oncology (2014)
Serial Transplantation of Methylcholanthrene-Treated Mammary Nodule Outgrowth Line D1&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Daniel Medina
Journal: JNCI Journal of the National Cancer Institute (1972)

Journal Article Serial Transplantation of Methylcholanthrene-Treated Mammary Nodule Outgrowth Line D1 Get access Daniel Medina Daniel Medina Department of Zoology and Its Cancer Research Genetics Laboratory, University of California, Berkeley, California 94720 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 5, May 1972, Pages 1363–1370, https://doi.org/10.1093/jnci/48.5.1363 Published: 01 May 1972 Article history Received: 13 October 1971 Accepted: 19 January 1972 Published: 01 May 1972
Ofloxacin in miliary tuberculosis
Authors: J Alegre, T Fernandez de Sevilla, V Falco, JM Martinez Vazquez
Journal: European Respiratory Journal (1990)

We report one case of severe miliary tuberculosis with liver failure and respiratory insufficiency in a twenty-seven year old patient. We emphasize the presence of hepatic, occular and vestibular toxicities secondary to the treatment and the usefulness of ofloxacin with cycloserine given for nine months.
Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial
Authors: K. Togsverd-Bo, C.S. Haak, D. Thaysen-Petersen, H.C. Wulf, R.R. Anderson, M. Haedesdal
Journal: British Journal of Dermatology (2012)

Photodynamic therapy (PDT) with methyl aminolaevulinate (MAL) is effective for thin actinic keratoses (AKs) in field-cancerized skin. Ablative fractional laser resurfacing (AFXL) creates vertical channels that facilitate MAL uptake and may improve PDT efficacy.To evaluate efficacy and safety of AFXL-assisted PDT (AFXL-PDT) compared with conventional PDT in field-directed treatment of AK.Fifteen patients with a total of 212 AKs (severity grade I-III) in field-cancerized skin of the face and scalp were randomized to one treatment with PDT and one treatment with AFXL-PDT in two symmetrical areas. Following curettage of both treatment areas, AFXL was applied to one area using 10 mJ per pulse, 0·12 mm spot, 5% density, single pulse (UltraPulse(®), DeepFx handpiece; Lumenis Inc., Santa Clara, CA, U.S.A.). MAL cream was then applied under occlusion for 3 h and illuminated with red light-emitting diode light at 37 J cm(-2). Fluorescence photography quantified protoporphyrin IX (PpIX) before and after illumination.At 3-month follow-up, AFXL-PDT was significantly more effective than PDT for all AK grades. Complete lesion response of grade II-III AK was 88% after AFXL-PDT compared with 59% after PDT (P = 0·02). In grade I AK, 100% of lesions cleared after AFXL-PDT compared with 80% after PDT (P = 0·04). AFXL-PDT-treated skin responded with significantly fewer new AK lesions (AFXL-PDT n = 3, PDT n = 11; P = 0·04) and more improved photoageing (moderate vs. minor improvement, P = 0·007) than PDT-treated skin. Pain scores during illumination (6·5 vs. 5·4; P = 0·02), erythema and crusting were more intense, and long-term pigmentary changes more frequent from AFXL-PDT than PDT (P = not significant). PpIX fluorescence was higher in AFXL-pretreated skin [7528 vs. 12,816 arbitrary units (AU); P = 0·003] and photobleached to equal intensities after illumination (AFXL-PDT 595 AU, PDT 454 AU; P = 0·59).AFXL-PDT is more effective than conventional PDT for treatment of AK in field-cancerized skin.
An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck.
Authors: T J Ervin, J R Clark, R R Weichselbaum, B G Fallon, D Miller, R L Fabian, M R Posner, C M Norris, S A Tuttle, D A Schoenfeld
Journal: Journal of Clinical Oncology (1987)

This study examines the role of combination chemotherapy with surgery and/or radiotherapy in the initial treatment of patients with advanced stage III and IV squamous-cell carcinoma of the head and neck (SCCHN). Two courses of initial (induction) cisplatin, bleomycin, and methotrexate with oral calcium leucovorin (PBM) were used with the principal intent of increasing the effectiveness of subsequent surgery and/or radiotherapy. Following induction chemotherapy and local treatment, disease-free patients who had responded to initial chemotherapy were entered into a randomized trial of adjuvant PBM. The response rates to induction PBM chemotherapy were a complete response (CR) rate of 26% and a partial response (PR) rate of 52%, for an overall response rate of 78%. A response to induction PBM was highly correlated with failure-free survival (P less than .0001). A Cox multistep regression analysis of potential prognostic factors was performed. After adjusting for the significant prognostic factors of performance status, initial tumor size, and primary tumor site, a response to induction chemotherapy remained independently associated with improved survival (P = .0002). The randomized trial of adjuvant chemotherapy demonstrated that such treatment significantly improved failure-free survival by decreasing local-regional failures. The benefit of adjuvant chemotherapy was particularly evident in patients who had a PR to induction chemotherapy (P = .01). The toxicity of this multidisciplinary approach was predictable and acceptable. Surgery and radiotherapy were not compromised by induction or adjuvant chemotherapy. Definitive evidence that chemotherapy can favorably influence survival awaits confirmation of these results by a randomized trial using a control arm of patients treated with conventional surgery and/or radiotherapy alone.
Systemic Therapy for Advanced Carcinoid Tumors: Where Do We Go From Here?
Authors: A. Scott Paulson, Emily K. Bergsland
Journal: Journal of the National Comprehensive Cancer Network (2012)

Carcinoid tumors are relatively indolent, but the treatment of advanced disease remains a challenge. Liver-directed therapies are a consideration in patients with liver-dominant disease. Somatostatin analogs (SSTa) are routinely used to control hormone-mediated symptoms (carcinoid syndrome), but the identification of systemic agents with antitumor efficacy has proven difficult. Aside from octreotide for small bowel carcinoid (which is associated with delayed progression), no treatment has proven antitumor activity. Chemotherapy seems to be of limited value. The role of interferon is also controversial; it is typically used after failure of octreotide. Peptide receptor radionuclide therapy may have activity in patients with SST receptor–expressing tumors, but randomized controlled trials are lacking. Advances in the understanding of the mechanisms underlying tumor progression have led to the identification of several potential therapeutic targets (including the vascular endothelial growth factor [VEGF] and mammalian target of rapamycin [mTOR] signaling pathways), but none has been definitively validated in carcinoid. Everolimus is associated with a trend toward improved progression-free survival in patients with progressive carcinoid, but is not approved for this indication. Therefore, a serious unmet need remains for additional therapeutic strategies for patients with advanced disease. Several avenues are under study, including the use of novel SSTa; VEGF and mTOR inhibitors; and agents that interfere with insulin growth factor 1 receptor and AKT signaling. Moving forward, optimizing patient selection based on clinical features or biomarkers holds promise for identifying individuals most likely to benefit from therapy.
Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients. Long-term follow-up of 243 patients
Authors: Bogdan Hajduk, Grzegorz Malek, Pawel Kuca, Witold Tomkowski
Journal: European Respiratory Journal (2013)

Background  Long-term management of patients with venous thromboembolism (VTE) who have received inferior vena cava (IVC) filters still remains under debate. Long-term and adequate anticoagulation can reduce a risk of thromboembolic complications in such patients.   Methods  In the period from 1993 to 2011 in our hospital 243 patients with VTE had indications to undergo IVC filter placement. The most frequent indication was recurrent pulmonary embolism (PE) despite anticoagulation. In all patients vitamin K antagonists (VKA) were given (INR target = 2.5). During follow-up there were assessed the rates of symptomatic pulmonary embolism, deep vein thrombosis (DVT) and IVC thrombosis. At least every two years physical examination and ultrasound surveillance were conducted. The ultrasound surveillance included assessment of the lower extremities deep veins and examination of the IVC filter. If filter clot was detected, graded intensities of anticoagulation were temporarily instituted, depending upon the clot burden.   Results  Symptomatic DVT and PE occurred in 46 (18.93%; 95% CI 14.50-24.32%) and 10 (including 2 fatal PE) (4.12%; 95% CI 2.25-7.41%) out of 243 patients respectively. There were 72 episodes of filter clot in 64 patients (26.34%; 95% CI 21.20-32.21%) Total occlusion of IVC filter was observed in 6 patients (2.47%; 95% CI 1.14-5.28%).   Conclusions  VTE patients with IVC filters can benefit from ultrasound surveillance of the IVC and adjusted anticoagulation if filter clot is detected.
Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study
Authors: C.-F. Kuo, L.-C. See, K.-H. Yu, I.-J. Chou, H.-C. Chang, M.-J. Chiou, S.-F. Luo
Journal: British Journal of Dermatology (2011)

Nationwide data on the epidemiology of dermatomyositis (DM) and polymyositis (PM) were limited.This study was to estimate the incidence, occurrence of cancer and mortality of DM and PM in Taiwan.Both the register of critical illness of the Taiwan National Health Insurance Research Dataset and the National Death Registry of Taiwan were used to calculate estimates of the incidence, cancer association, and mortality of DM and PM between 2003 and 2007.A total of 803 DM and 500 PM cases were identified between 2003 and 2007. Mean age at diagnosis was 44·0 ± 18·3 years for DM and 49·2 ± 15·9 years for PM. The overall annual incidences of DM and PM were 7·1 (95% CI 6·6-7·6) and 4·4 (95% CI 4·0-4·8) cases per million population. The incidence of both DM and PM increased with age and reached a peak at age 50-59 years. One hundred and eleven (13·8%) patients with DM and 31 (6·2%) patients with PM had cancers. The diagnosis of most cancers was made after the diagnoses of DM (n = 71; 64·0%) and PM (n = 21; 67·7%). Overall, the standardized incidence ratios (SIR) for cancer were 5·36 (4·12-6·87) and 1·80 (1·10-2·79) among patients with DM and PM; however, during the first year, SIRs for cancer were 24·55 (95% CI 18·62-31·79) and 9·17 (95% CI 14·82-15·93) in patients with DM and PM, respectively. The most common types of cancer were nasopharyngeal cancer for men and breast cancer for women. Patients with DM and PM had standardized mortality ratios of 7·68 (6·41-9·01) and 5·29 (4·28-6·48).This study reports robust estimates of important aspects of the epidemiology of both DM and PM in Taiwan. This highlights the rarity of these diseases, and their associated cancer risks and increased mortality.
Further Studies on Inhibition of Epstein-Barr Virus Release by Bovine Serum: Partial Purification and Characterization of the Inhibitor2
Authors: Masa-aki Matsumoto, Yoshifumi Tada, Junji Yamaguchi, Takeshi Sairenji, Yorio Hinuma
Journal: JNCI Journal of the National Cancer Institute (1980)

The antivirus release factor (AVRF) was extracted from adult bovine serum and was partially purified in three steps by 1) ammonium sulfate precipitation, 2) Sephadex G-200 chromatography, and 3) DEAE-Sephadex chromatography, procedures that together increased specific activity 160 times. In molecular sieve chromatography, AVRF was found in fractions close to IgM. The AVRF activity was sensitive to KIO4 (0.04 M) but not to trypsin (0.1%), UV irradiation, ethyl ether, and heating at 56 degrees C for 30 minutes. The AVRF neither neutralized infectivity of Epstein-Barr virus (EBV) from the P3HR-1 cell line nor inhibited intracellular virus yields at concentrations that inhibited release of virus into culture fluid. Cellular release of two other strains of EBV (QIMR-WIL and B95-8) was also inhibited by AVRF. Electron microscopic examination of P3HR-1 cells cultured in the presence of AVRF revealed peculiar interacytoplasmic vacuoles containing many mature virus particles with tail-like structures.
Reverse Transcriptase and 70S RNA in Supernatant From a Human Cell Line2
Authors: Michael Vincent Viola
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Reverse Transcriptase and 70S RNA in Supernatant From a Human Cell Line Get access Michael Vincent Viola, M.D. Michael Vincent Viola, M.D. Howard University School of Medicine, Department of Medicine, Washington, D.C. 20001 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 5, May 1973, Pages 1175–1178, https://doi.org/10.1093/jnci/50.5.1175 Published: 01 May 1973 Article history Received: 20 November 1972 Accepted: 10 January 1973 Published: 01 May 1973
HLA–B27 Subtype Oligomerization and Intracellular Accumulation Patterns Correlate With Predisposition to Spondyloarthritis
Authors: Cindy Jeanty, Adèle Sourisce, Aurélie Noteuil, Nadège Jah, Aurore Wielgosik, Ingrid Fert, Maxime Breban, Claudine André
Journal: Arthritis & Rheumatology (2014)

Mechanisms underlying the striking association of spondyloarthritis (SpA) with the class I major histocompatibility complex molecule HLA-B27 remain poorly understood. SpA-like disease develops spontaneously in B*2705-transgenic rats, in conjunction with high HLA-B27 expression levels. This study was undertaken to examine the effects of increased expression of HLA-B27 alleles that are differentially associated with SpA on oligomerization and intracellular redistribution. HeLa cells were transfected with complementary DNA encoding for HLA-B proteins fused to yellow fluorescent protein and/or Renilla luciferase and harvested at an early phase and a later phase of expression. We monitored HLA-B intracellular trafficking and localization by means of microscopy and live-cell imaging. Bioluminescence resonance energy transfer (BRET) and Western blotting were used to monitor HLA-B oligomerization. At low expression levels, BRET signals were similarly elevated for all SpA-associated HLA-B27 alleles tested, but were lower for the nonassociated B*2706. Of note, at higher expression levels, HLA-B27 signals remained steady while signal for HLA-B7 decreased sharply, reaching the level observed for B*2706. This was due at least in part to a decreased oligomer proportion without unfolded protein response outbreak. Such differential behavior was not abrogated by proteasome inhibition. With increased expression, all HLA-B proteins accumulated to a high density in cytoplasmic vesicles with labile form and size. The extent of this phenomenon was closely correlated with the level of association with predisposition to SpA. To our knowledge, this is the first report of a correlation between the level of predisposition to SpA conferred by HLA-B27 alleles and their biochemical behavior. These findings open new perspectives for understanding the pathogenicity of HLA-B27.
Phase I Study of Chimeric Human/Murine Anti–Ganglioside G<sub>D2</sub>Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children’s Cancer Group Study
Authors: M. Fevzi Ozkaynak, Paul M. Sondel, Mark D. Krailo, Jacek Gan, Brad Javorsky, Ralph A. Reisfeld, Katherine K. Matthay, Gregory H. Reaman, Robert C. Seeger
Journal: Journal of Clinical Oncology (2000)

PURPOSE: Ganglioside G D2 is strongly expressed on the surface of human neuroblastoma cells. It has been shown that the chimeric human/murine anti-G D2 monoclonal antibody (ch14.18) can induce lysis of neuroblastoma cells by antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The purposes of the study were (1) to determine the maximum-tolerated dose (MTD) of ch14.18 in combination with standard dose granulocyte-macrophage colony-stimulating factor (GM-CSF) for patients with neuroblastoma who recently completed hematopoietic stem-cell transplantation (HSCT), and (2) to determine the toxicities of ch14.18 with GM-CSF in this setting. PATIENTS AND METHODS: Patients became eligible when the total absolute phagocyte count (APC) was greater than 1,000/μL after HSCT. ch14.18 was infused intravenously over 5 hours daily for 4 consecutive days. Patients received GM-CSF 250 μg/m 2 /d starting at least 3 days before ch14.18 and continued for 3 days after the completion of ch14.18. The ch14.18 dose levels were 20, 30, 40, and 50 mg/m 2 /d. In the absence of progressive disease, patients were allowed to receive up to six 4-day courses of ch14.18 therapy with GM-CSF. Nineteen patients with neuroblastoma were treated. RESULTS: A total of 79 courses were administered. No toxic deaths occurred. The main toxicities were severe neuropathic pain, fever, nausea/vomiting, urticaria, hypotension, mild to moderate capillary leak syndrome, and neurotoxicity. Three dose-limiting toxicities were observed among six patients at 50 mg/m 2 /d: intractable neuropathic pain, grade 3 recurrent urticaria, and grade 4 vomiting. Human antichimeric antibody developed in 28% of patients. CONCLUSION: ch14.18 can be administered with GM-CSF after HSCT in patients with neuroblastoma with manageable toxicities. The MTD is 40 mg/m 2 /d for 4 days when given in this schedule with GM-CSF.
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
Authors: R Colwill, M Crump, F Couture, R Danish, A K Stewart, D M Sutton, J G Scott, S B Sutcliffe, J M Brandwein, A Keating
Journal: Journal of Clinical Oncology (1995)

PURPOSE To evaluate the efficacy of carmustine (BCNU), etoposide, cytarabine (Ara-C), and melphalan (mini-BEAM) as salvage therapy in patients with relapsed or refractory Hodgkin's disease who were potentially eligible to undergo intensive therapy and autologous bone marrow transplantation (ABMT). PATIENTS AND METHODS Forty-four patients with refractory or relapsed Hodgkin's disease after front-line combination chemotherapy referred for consideration of ABMT were treated with mini-BEAM (BCNU 60 mg/m2 on day 1, etoposide 75 mg/m2 on days 2 to 5, Ara-C 100 mg/m2 twice per day on days 2 to 5, and melphalan 30 mg/m2 on day 6) to maximum response. Eleven patients were refractory to primary chemotherapy. Twenty-three patients were treated in first relapse and 10 in second or subsequent relapse; 21 received mini-BEAM as their first salvage regimen. Patients were restaged to determine disease status immediately before intensive therapy and transplant. RESULTS The overall response rate was 84% (exact 95% confidence interval [CI], 70% to 92%), with a complete response (CR) rate of 32% (95% CI, 20% to 47%) and a partial response (PR) rate of 52%. No treatment-related deaths were observed. Myelosuppression was the major toxicity. Almost all patients required platelet transfusions. Eighty-four percent were given RBC transfusions, and 54% required intravenous antibiotics for fever while neutropenic. CONCLUSION Mini-BEAM is a safe and effective regimen for treatment of refractory or relapsed Hodgkin's disease. Further studies are required to determine if responding patients have improved disease-free survival (DFS) after intensive therapy and ABMT.
Racial variation in human leukocyte antigen frequency in insulin-dependent diabetic nephropathy. The South-Eastern Organ Procurement Foundation.
Authors: B I Freedman, M A Espeland, E R Heise, J Evans, V J Canzanello
Journal: Journal of the American Society of Nephrology (1993)

Black patients with insulin-dependent diabetes mellitus are at increased risk for the development of diabetic nephropathy compared with white patients. To determine if genetic differences associated with the HLA system account for racial variation in insulin-dependent diabetes mellitus-induced nephropathy, serologically defined HLA phenotypes from renal transplant recipients and donors in the South-Eastern Organ Procurement Foundation database from 1982 to 1986 were analyzed. Renal transplant recipients (N = 1,531) with insulin-dependent diabetes mellitus-induced renal failure as the cause of ESRD (patients) were compared with 4,506 race-matched, nondiabetic cadaveric kidney donors (controls). Log-linear models were used to assess the relationship between insulin-dependent diabetes mellitus-induced renal failure and prevalence of each HLA phenotype. Bonferroni adjustments of P values were used to correct for multiple comparisons. A comparison of HLA frequencies in patients with insulin-dependent diabetes mellitus-induced renal failure demonstrated the presence of racial differences beyond those normally present between the black and white populations. Blacks, compared with whites, had increased frequencies of HLA-B62 (odds ratio [OR] black:white, 6.13:1.97; P < 0.02) and HLA-DR9 (OR black:white, 4.82:1.57; P < 0.008) and decreased frequencies of HLA-A1 (OR white:black, 1.56:0.8; P < 0.008) and HLA-DR3 (OR white:black, 4.9:2.82; P < 0.004). These results suggest that differences in HLA frequency may account, in part, for the observed racial variation in incidence of diabetic nephropathy. In addition, several antigens in positive and negative association with diabetic nephropathy were identified within each race.